A detailed history of Schroder Investment Management Group transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Schroder Investment Management Group holds 15,000 shares of PRTA stock, worth $195,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Previous 15,000 -0.0%
Holding current value
$195,750
Previous $309,000 19.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$19.54 - $26.15 $15,065 - $20,161
-771 Reduced 4.89%
15,000 $309,000
Q1 2024

May 14, 2024

BUY
$24.75 - $40.66 $7,870 - $12,929
318 Added 2.06%
15,771 $390,000
Q4 2023

Feb 13, 2024

BUY
$32.31 - $52.32 $362,550 - $587,082
11,221 Added 265.15%
15,453 $561,000
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $11,068 - $16,520
234 Added 5.85%
4,232 $204,000
Q2 2023

Aug 11, 2023

BUY
$48.26 - $78.59 $192,943 - $314,202
3,998 New
3,998 $272,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $612M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.